Effect of a CCK-1R Agonist on Food Intake in Humans
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK)
agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia
Nervosa. The study will be conducted in phases. First, an effective dose for reducing food
intake, when normal subjects eat normally will be attained. Next, it will be determined
whether intake at this dose is reduced in control subjects instructed to eat to capacity. If
the dose is still effective compared to placebo, the same dose will be tested in patients
with bulimia nervosa.